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Abstract Lipopolysaccharide (LPS) induction of TNF-K re-
lease is a central event in the pathophysiology of Gram-negative
bacterial septicaemia. Lung surfactant protein A (SP-A)
mediates pathogen/host cell interactions. Binding of SP-A to
Pseudomonas aeruginosa LPS and the effects of SP-A with LPS
or whole bacteria on buffy coat cells were investigated. SP-A
interacts with P. aeruginosa LPS in a concentration and calcium
dependent manner, either through the lipid A portion of LPS or
through another lectin/carbohydrate interaction. SP-A decreased
TNF-K secretion induced by bacteria or LPS from buffy coat
cells, in a concentration dependent manner.
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1. Introduction
Pseudomonas aeruginosa is an opportunistic lung pathogen
which adheres to cilia of damaged or exfoliated human respi-
ratory cells [1]. In cystic ¢brosis, staphylococcal airway injury
permits colonisation by P. aeruginosa. Patients are at ¢rst
colonised with non-mucoid strains, but later mucoid variants
emerge. The extracellular alginate they produce increases their
adherence to ciliated epithelium [2]. Despite the high antibody
levels present against such strains and intensive antibiotic
therapy, they cannot always be completely eradicated. Algi-
nate also interferes with antibody coating and inhibits phag-
ocytosis of P. aeruginosa [3]. Bacterial proteases produced by
P. aeruginosa cause signi¢cant damage to the airways. Elas-
tase and alkaline protease are secreted in vivo over prolonged
periods in the airways [4]. Elastase increases the permeability
of epithelial cells and destroys tight junctions.
Lipopolysaccharide (LPS) is a complex glycolipid and the
major component of the outermost membrane of Gram-neg-
ative bacteria. LPS provides a potent and pleiotropic stimulus
for immune cells, both in vitro and in vivo [5,6], and it has
been implicated in the clinical syndrome of Gram-negative
septic shock. Although the polysaccharide portion of LPS
varies considerably, the lipid A domain is highly conserved
between otherwise diverse strains of Gram-negative bacteria.
The lipid A portion of the molecule is responsible for most of
the biological e¡ects of LPS [5,7].
LPS induction of cytokine release, particularly tumour ne-
crosis factor-K (TNF-K) and interleukin (IL)-1 is probably the
central event in the pathophysiology of Gram-negative bacte-
rial septicaemia. LPS stimulation of leukocytes and endothe-
lial cells leads to the release of cytokines and in£ammatory
mediators that enhance host defences against bacteria [8]. In
acute P. aeruginosa infections, the organism is covered with a
smooth LPS and, during chronic lung infections, an altered
rough LPS is present [9].
There are several cell surface receptors for LPS. CD14,
which is expressed on the surface of monocytes and neutro-
phils [10,11], binds LPS with high a⁄nity. Anti-CD14 anti-
bodies block cellular LPS responses [12]. Low or intermediate
concentrations of LPS do not induce cellular responses in
CD14 knockout mice [13,14]. Conversely transgenic mice
that overexpress CD14 show hypersensitivity to LPS [15].
The initial rate and extent of CD14-dependent internalisation
of LPS increases with LPS aggregate size [16]. Cellular re-
sponses to LPS are increased by the LPS-binding protein
(LBP), which binds LPS aggregates and transfers LPS mono-
mers to CD14 [17,18]. CD18, the L2 integrin which is a sub-
unit of complement receptors CR3 and CR4 [19], is a trans-
membrane signalling receptor for LPS [20]. The macrophage
scavenger receptor type A also binds LPS and protects against
excessive cytokine release by activated macrophage [21]. At
concentrations of LPS in excess of 100 ng/ml, the activation
of cells can take place in the absence of LBP and CD14. The
low-a⁄nity signalling receptor on neutrophils and other leu-
kocytes is thought to be L-selectin [22]. Whole bacteria are
thought to interact with more than one cell surface receptor.
Cell wall preparations from group B streptococci type III
induce TNF-K release from human monocytes through inter-
action with CD14 and CD18 [19].
Lung surfactant protein A (SP-A) is a member of the col-
lectin family of mammalian proteins. Collectins contain both
globular domains, the calcium-dependent carbohydrate bind-
ing domains (C-type lectins), and extended collagen-like re-
gions. Other members of the collectin family are lung surfac-
tant protein D and the plasma lectins, mannose binding lectin,
conglutinin and CL-43 [23^25]. SP-A is an abundant protein
associated with surfactant that has roles in the structure
[26,27], metabolism [28], and function [29,30] of surfactant
as well as in host defence [31].
The range of immunologically signi¢cant targets which SP-
A recognises is not completely known. The current hypothesis
is that SP-A is likely to bind to a wide range of inhaled
materials and to mediate their interaction with cells (phago-
cytes or specialised epithelium) as part of a natural defence
system [23^25,32,33]. SP-A has been shown to play a role in
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host defence mechanisms, and is known to bind to in£uenza
virus [34], Mycobacterium tuberculosis [35] and Klebsiella
pneumoniae [36].
SP-A binds speci¢cally and competitively to alveolar mac-
rophages. SP-A positively a¡ects the ability of the alveolar
macrophage to perform host defence functions, such as phag-
ocytosis [37] and generation of reactive oxygen species [38].
However, the role of the collectins in cytokine induction is
currently unclear; some investigators have observed increased
TNF-K induction [39^41] while others have seen the opposite
e¡ect [42,43] and there has been one report where SP-A alone
increased TNF-K release, but had the opposite e¡ect in the
presence of LPS [44]. We have looked at the e¡ect of SP-A on
total blood leukocytes which contain a receptor capable of
interacting with SP-A [45], rather than limiting the study to
one cell type. This is the ¢rst investigation of TNF-K release
using SP-A and a respiratory pathogen.
2. Methods
2.1. Puri¢cation of SP-A
SP-A was puri¢ed from human lung lavage £uid from alveolar
proteinosis patients by the method of Strong et al. [46]. Brie£y, hu-
man bronchoalveolar lavage £uid was made 10 mM CaCl2 and in-
cubated at 4‡C overnight to maximise SP-A aggregation. The suspen-
sion was clari¢ed by centrifugation at 10 000Ug for 1 h at 4‡C. The
resulting pellet was extracted with 6 M urea, 20 mM Tris-HCl, pH
7.4, 5 mM EDTA (100 ml per gram of pellet). The extract was cen-
trifuged at 10 000Ug for 1 h and the supernatant dialysed against 10
mM Tris-HCl, pH 7.4, 5 mM EDTA. The dialysate was made 10 mM
CaCl2 and the pH adjusted to 7.4, before it was loaded to a 15-ml
column bed of maltose-agarose (Sigma, Poole, UK), equilibrated with
10 mM Tris-HCl, pH 7.4, 10 mM CaCl2. After loading, the column
was washed to background with 10 mM Tris-HCl, pH 7.4, 10 mM
CaCl2. Non-speci¢cally-bound proteins were eluted with 10 mM Tris-
HCl, pH 7.4, 1 M NaCl, 10 mM CaCl2. SP-D was removed with 100
mM MnCl2, 10 mM Tris-HCl, pH 7.4. The remaining bound proteins
were eluted with a gradient of 0^50 mM EDTA in 10 mM Tris-HCl,
pH 7.4. Fractions containing SP-A were pooled, concentrated and
further puri¢ed by gel ¢ltration (Superose 6; Amersham Pharmacia
Biotech, St. Albans, UK).
Some preparations of SP-A were found to cause induction of TNF-
K release from bu¡y coat (BC) cells. To ensure a low background of
TNF-K production, SP-A was incubated for 30 min at room temper-
ature with polymyxin B agarose (Sigma) to remove LPS and protein
G agarose (Sigma) to remove IgG, prior to use.
2.2. Source of bacteria and bacterial products
Pseudomonas aeruginosa was obtained from National Collection of
Industrial and Marine Bacteria, Aberdeen, UK, strain reference
NCIMB 12050. P. aeruginosa was grown in Luria broth at 37‡C.
LPS was obtained from this strain of P. aeruginosa as described be-
low. Lipid A was purchased from Sigma.
2.3. Puri¢cation of LPS
LPS was puri¢ed from P. aeruginosa by the method of Darveau and
Hancock [47] with slight modi¢cations. Bacterial cells were harvested
in the mid-logarithmic phase and suspended at 10 ml/g (wet weight) in
10 mM Tris-HCl (pH 8.0), 2 mM MgCl2. The cells were lysed in a
bead beater (Stratech Scienti¢c, UK) for 3 min. The cell lysate was
sonicated for 2U30 s at a probe intensity of 75% and the suspension
was incubated at 37‡C for 2 h. After incubation, the solution was
made 0.1 M tetrasodium EDTA, 10 mM Tris-HCl and 2% SDS at
a pH of V9.5. The sample was then subjected to centrifugation at
50 000Ug for 30 min at 20‡C to remove peptidoglycan. The super-
natant was decanted and 200 Wg/ml pronase (Sigma) was added. The
sample was incubated overnight at 37‡C with constant shaking. Two
volumes of 0.375 M MgCl2 in 95% ethanol were added, mixed and
cooled to 0‡C. The sample was then centrifuged at 12 000Ug for 15
min at 2‡C. The pellet obtained was suspended in 25 ml of 2% SDS-
0.1 M tetrasodium EDTA, dissolved in 10 mM Tris-HCl (pH 8), and
sonicated as described above. Incubation at 85‡C for 30 min ensured
denaturation of SDS-resistant proteins. Pronase was added to 25 Wg/
ml, and the sample was incubated overnight at 37‡C with constant
agitation. After incubation, LPS was precipitated with two volumes of
0.375 M MgCl2 in 95% ethanol at 0‡C as described above, followed
by centrifugation at 12 000Ug for 15 min at 2‡C.
The pellet was resuspended in 15 ml of 10 mM Tris-HCl (pH 8),
sonicated as described above, and centrifuged at 1000 rpm to remove
insoluble Mg2-EDTA crystals. The supernatant was then centrifuged
at 200 000Ug for 2 h at 15‡C in the presence of 25 mM MgCl2. The
pellet of LPS was resuspended in distilled water.
2.4. Solid phase binding assays
Microtitre plate wells (Polysorp; Nunc, Kamstrup, Denmark), were
coated with LPS from P. aeruginosa (100 Wl per well ; 1 Wg per well) in
100 mM Na2CO3 coating bu¡er (pH 9.6) for 2 h at room temper-
ature. The plates were then washed four times with 250 Wl/well of
PBS-0.05% (w/v) Tween-20 (PBS-Tween) before the non-speci¢c sites
were blocked with BSA (5%, w/v) in PBS-Tween (300 Wl per well). The
bound LPS was incubated with serial dilutions of SP-A (100 Wl per
well ; maximum 10 Wg) in PBS, containing CaCl2 (0.5 mM) with or
without EDTA (maximum 5 mM) or mannan (maximum 50 Wg/ml) or
Lipid A (maximum 100 Wg/ml) for 2 h at room temperature. After
further washing, polyclonal rabbit anti-human SP-A in PBS-Tween-
0.5 mM CaCl2 was added to each well (total 100 Wl). Incubations with
primary antibody were carried out for 2 h at room temperature. The
plates were washed four times in PBS-Tween-CaCl2 and alkaline-
phosphatase-conjugated goat antibodies to rabbit IgG (Sigma) added
and left for 2 h at room temperature. After four further washes with
200 Wl/well PBS-Tween, 100 Wl/well of p-nitrophenyl phosphate
(pNPP; 1 mg/ml; Sigma) in 25 mM Tris-HCl, 5 mM CaCl2, 5 mM
MgCl2, pH 7.4, was added and incubated for 30 min or until su⁄cient
colour developed. The plates were read at 405 nm.
2.5. Preparation of bu¡y coat cells
Bu¡y coat (BC) cells were prepared from EDTA treated fresh hu-
man blood (50 ml). The blood was centrifuged (10 min, 800Ug). The
interface between the plasma and red blood cells, which contains the
leukocytes, was removed for further centrifugation (6 min, 800Ug).
The white cell pellet was washed twice in PBS and pelleted by cen-
trifugation (6 min, 450Ug). The pellet was resuspended in equal vol-
umes of plasma and RPMI 1640 media containing 2 mM glutamine
(Gibco-BRL, Paisley, UK). Each test required approximately 1U107
cells in 500 Wl.
2.6. Cytokine release assay
To investigate the e¡ect of SP-A on the release of TNF-K from BC
cells, puri¢ed SP-A (100 Wl ; ¢nal concentration of 5.7, 2.9, 1.4 and 0.7
Wg/ml) was incubated with BC cells (500 Wl) in the presence of P.
aeruginosa (100 Wl of 1:5000 log phase culture (OD600 = 0.5)) or P.
aeruginosa LPS (10 Wg/ml) for 4 h at 37‡C. BC cells were incubated
with medium or SP-A (1.4 Wg/ml) as negative controls. Positive con-
trols contained P. aeruginosa or P. aeruginosa LPS and BC cells. After
4 h, the cells were removed by brief centrifugation and the super-
natants were assayed for TNF-K by ELISA (RpD Systems, Oxon,
UK).
3. Results
3.1. Interaction of SP-A with P. aeruginosa LPS
SP-A has previously been shown to interact with LPS from
various organisms [42,44,48] in a calcium dependent manner.
The interaction of puri¢ed P. aeruginosa LPS and puri¢ed
human SP-A was investigated by coating microtitre wells
with LPS and probing with SP-A. Under these conditions,
SP-A bound to P. aeruginosa LPS in a concentration depend-
ent manner (Fig. 1A). The maximum concentration of SP-A
available was insu⁄cient to saturate, but an approach to sat-
uration was observed.
In order to investigate how SP-A interacts with P. aerugi-
nosa LPS, EDTA was added to chelate calcium ions, or man-
nan was added to compete for the sugar binding sites of SP-A,
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or lipid A was added to compete for lipid A binding. Removal
of calcium ions with EDTA almost completely inhibited the
binding of SP-A to P. aeruginosa LPS (Fig. 1B). Competition
for SP-A binding sites between the ¢xed concentration of P.
aeruginosa LPS and variable concentration of mannan re-
sulted in a signi¢cant but low level of inhibition of SP-A
binding (Fig. 1C). Competition for SP-A carbohydrate bind-
ing sites between the ¢xed concentration of P. aeruginosa LPS
and variable concentration of lipid A resulted in a signi¢cant
level of inhibition of SP-A binding (Fig. 1D). The major in-
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Fig. 1. Binding of SP-A to P. aeruginosa LPS. Each well of a microtitre plate was coated with 1 Wg of LPS and blocked. A: SP-A was incu-
bated with LPS in the presence of 0.5 mM Ca2 at the concentrations shown. Polyclonal anti-SP-A antibodies were followed by goat anti-rab-
bit IgG-alkaline phosphatase. The assay was developed with pNPP and the optical density was read at 405 nm (OD405). The amount of SP-A
bound was taken as a direct reading from the optical density (arbitrary units). Inhibition of SP-A binding was determined at 5 Wg/ml SP-A
with (B) EDTA, (C) mannan and (D) Lipid A (all at concentrations shown). Inhibition (%) was calculated from the OD405 of the 0.5 mM
Ca2 value and the OD405 values obtained with inhibitors.
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teraction between SP-A and LPS is through the lipid A por-
tion of LPS, which can be inhibited by 70% by competition
with free Lipid A. However, carbohydrate binding via the
CRD of SP-A appears to make a contribution to the inter-
action; addition of mannan inhibits SP-A binding by 30%.
3.2. Cytokine release assay
Interaction between leukocytes and LPS is known to lead to
the secretion of TNF-K [8]. Incubation of LPS with BC cells
induced TNF-K release (Fig. 2A). Addition of SP-A alone to
these cells had little e¡ect on the basal level of TNF-K pro-
duced. In the presence of LPS, addition of SP-A led to a
decrease in TNF-K secretion and the decrease was propor-
tional to the concentration of SP-A added (Fig. 2A).
Incubation of whole bacteria with BC cells induced a sub-
stantial release of TNF-K (greater than observed with LPS
alone). In the presence of bacteria, addition of SP-A greatly
reduced the release of TNF-K, such that at a ¢nal SP-A con-
centration of 2.9 Wg/ml, the BC cells released only 20% of the
TNF-K of the positive control and this decreased to 1% in the
presence of 5.7 Wg/ml (Fig. 2B).
4. Discussion
The goals of our investigation were to determine whether
SP-A interacts with the respiratory pathogen, Pseudomonas
aeruginosa, and to provide more data on the e¡ects of SP-A
induction of TNF-K. Previous, contradictory studies on the
e¡ect of SP-A in induction of TNF-K used slightly di¡erent
cell types [40,42]. We have used total blood leukocytes which
contain a receptor capable of interacting with SP-A [45].
Our results show that SP-A can interact with P. aeruginosa
LPS in a concentration and calcium dependent manner, con-
sistent with the ¢ndings of other investigators for LPS from
other organisms [42,44,48]. However, SP-A binding to P.
aeruginosa LPS is partially inhibited by mannan, unlike the
interaction with Salmonella minnesota Re-LPS or Escherichia
coli J5-LPS [48]. The mode of interaction of SP-A with lipid A
is uncertain. Interaction may be with the charged saccharides,
or with the fatty acids. SP-A is also likely to interact with
other sugars in LPS; this interaction will be dependent on
the carbohydrate composition. Our results highlight the di¡er-
ence in polysaccharide components of LPS from di¡erent or-
ganisms [5,7].
The cytokine release assay suggests that LPS or bacteria
interact with BC cells in a di¡erent manner when SP-A is
present. This could be due to adhesion of the LPS/SP-A or
bacterium/SP-A complex via an SP-A receptor rather than via
one of the known receptors: CD14, CD18 or L-selectin. Al-
ternatively, SP-A may prevent the interaction of cell surface
receptors with LPS or bacteria by competing for binding sites.
SP-A binding to the lipid A portion of LPS may break up
LPS micelles, an event which would produce smaller aggre-
gates of LPS. Smaller aggregates are known to be less e⁄cient
at inducing a TNF-K response [16], probably because they are
unable to crosslink receptors.
The SP-A concentration dependence of TNF-K release
could indicate that when there is su⁄cient SP-A present to
deal with an infection, then the cells do not signal a require-
ment for help. However, as soon as there is more LPS or
bacteria than can be dealt with by this part of the innate
immune system then the endotoxin or pathogen can interact
with LBP and CD14. This would then lead to TNF-K secre-
tion to stimulate other arms of the immune system which can
dispose of LPS, such as macrophage scavenger receptors [21],
or to recruit in£ammatory cells. This concept is supported by
the observation that SP-A concentration inversely correlated
with the number of in£ammatory cells in bronchoalveolar
lavage £uid from cystic ¢brosis patients (A. Mander, personal
communication). SP-A mediated removal of LPS represents
an immunologically similar mechanism to the scavenger re-
ceptor [21] ; each reduces the amount of proin£ammatory cy-
tokine released.
We conclude that SP-A binds to P. aeruginosa, at least
partially through LPS, and prevents TNF-K release probably
through sterically hindering interaction of the microorganism
with cell surface receptors other than SP-A receptors.
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